Thousands of Arthritis Patients May Have Undiagnosed Lung Disease

Thousands of patients with rheumatoid arthritis may be unknowingly living with a serious and potentially deadly lung disease, according to new research. The condition, known as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), can cause significant scarring and inflammation in the lungs, leading to breathing difficulties.

Rheumatoid arthritis is an autoimmune disorder that affects over 400,000 people in the UK, primarily causing joint pain and inflammation. However, the latest findings, published in the medical journal The Lancet Respiratory Medicine, identify RA-ILD as a critical complication that can severely impact a person's health and quality of life.

Experts estimate that one in six individuals with rheumatoid arthritis develop some form of lung abnormality, and one in ten go on to develop RA-ILD. Early detection is crucial, as timely treatment with anti-inflammatory medications can slow lung scarring and help preserve respiratory function. Common treatments include immunosuppressants and anti-fibrotic drugs.

If left untreated or diagnosed late, RA-ILD can lead to severe outcomes and can be fatal. Initial symptoms often include a persistent dry cough and shortness of breath during physical activity, alongside general fatigue and weakness. Less common signs can include a "velcro-like" crackling sound in the lungs, finger and toe clubbing, and a hoarse voice.

Several factors increase the risk of developing RA-ILD. These include being male, being over the age of 60, and having a history of smoking. More severe symptoms of rheumatoid arthritis itself can also contribute to the onset of lung complications.

In response to these findings, experts are advocating for increased screening of rheumatoid arthritis patients who exhibit these high-risk criteria. The recommendations aim to guide clinicians in identifying lung disease earlier, improving patient monitoring, and determining the appropriate timing for treatment interventions. Early identification and management are key to improving prognosis and preventing the severe consequences associated with RA-ILD.